242 related articles for article (PubMed ID: 12794755)
1. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
Endoh H; Yatabe Y; Shimizu S; Tajima K; Kuwano H; Takahashi T; Mitsudomi T
Int J Cancer; 2003 Aug; 106(1):45-51. PubMed ID: 12794755
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
3. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
5. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
[TBL] [Abstract][Full Text] [Related]
7. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
Dammann R; Takahashi T; Pfeifer GP
Oncogene; 2001 Jun; 20(27):3563-7. PubMed ID: 11429703
[TBL] [Abstract][Full Text] [Related]
8. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.
Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P
BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876
[TBL] [Abstract][Full Text] [Related]
9. K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
van Engeland M; Roemen GM; Brink M; Pachen MM; Weijenberg MP; de Bruïne AP; Arends JW; van den Brandt PA; de Goeij AF; Herman JG
Oncogene; 2002 May; 21(23):3792-5. PubMed ID: 12032847
[TBL] [Abstract][Full Text] [Related]
10. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection.
Kuzmin I; Liu L; Dammann R; Geil L; Stanbridge EJ; Wilczynski SP; Lerman MI; Pfeifer GP
Cancer Res; 2003 Apr; 63(8):1888-93. PubMed ID: 12702579
[TBL] [Abstract][Full Text] [Related]
13. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.
Dammann R; Schagdarsurengin U; Liu L; Otto N; Gimm O; Dralle H; Boehm BO; Pfeifer GP; Hoang-Vu C
Oncogene; 2003 Jun; 22(24):3806-12. PubMed ID: 12802288
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
18. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
19. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
20. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
